What question did this study set out to answer?

This trial evaluated the efficacy and safety of efepoetin alfa for treating anemia in dialysis patients and informed dose selection for phase 3 trials.

July 10, 2026Kidney Research and Clinical PracticeOpen Access

Efficacy, safety, and dose selection of efepoetin alfa in anemic patients on maintenance dialysis: a phase 2, randomized, multicenter, active-controlled trial

View Full Paper

Ask AI

Bookmark

This trial evaluated the efficacy and safety of efepoetin alfa for treating anemia in dialysis patients and informed dose selection for phase 3 trials.
Multicenter, open-label, active-controlled design
Involved hemodialysis (HD) and peritoneal dialysis (PD) patients with hemoglobin <10 g/dL
Patients randomized to receive different doses of efepoetin alfa or control therapies over 12 weeks.
In HD cohort, mean Hb increased 3.19 g/dL for efepoetin alfa (5 or 8 µg/kg Q1W) versus 2.52 g/dL for darbepoetin alfa.
In PD cohort, mean Hb increased 2.69 g/dL (5 µg/kg Q2W) and 3.48 g/dL (8 µg/kg Q2W) for efepoetin alfa; control group increased by 2.01 g/dL.
Exploratory analysis suggested 4 µg/kg Q2W efepoetin alfa as an appropriate starting dose for phase 3 trials.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial demonstrates efficacy of efepoetin alfa in enhancing hemoglobin levels in dialysis patients, implying potential for improved anemia management.

Cite This Study

Ko et al. (2026) studied this question.

synapsesocial.com/papers/6a508da76eeac72a437a0fdc https://doi.org/10.23876/j.krcp.26.080

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates efficacy of efepoetin alfa in enhancing hemoglobin levels in dialysis patients, implying potential for improved anemia management.

Efficacy, safety, and dose selection of efepoetin alfa in anemic patients on maintenance dialysis: a phase 2, randomized, multicenter, active-controlled trial

Key Points

Discussion

Implication

Cite This Study

Efficacy, safety, and dose selection of efepoetin alfa in anemic patients on maintenance dialysis: a phase 2, randomized, multicenter, active-controlled trial

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider